Complete financial analysis of Benitec Biopharma Inc. (BNTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Benitec Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nippon Rietec Co.,Ltd. (1938.T) Income Statement Analysis – Financial Results
- Newell Brands Inc. (0K7J.L) Income Statement Analysis – Financial Results
- Restar Holdings Corporation (3156.T) Income Statement Analysis – Financial Results
- Binero Group AB (publ) (BINERO.ST) Income Statement Analysis – Financial Results
- Emergent Health Corp (EMGE) Income Statement Analysis – Financial Results
Benitec Biopharma Inc. (BNTC)
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.00K | 75.00K | 73.00K | 59.00K | 97.00K | 11.32M | 455.45K | 450.31K | 346.51K | 829.13K | 1.02M | 545.73K |
| Cost of Revenue | 108.00K | 381.00K | 9.00K | 123.00K | 268.07K | 426.51K | 331.30K | 209.02K | 103.80K | 30.68K | 37.66K | 176.13K |
| Gross Profit | 108.00K | -306.00K | 64.00K | -64.00K | -171.07K | 10.89M | 124.15K | 241.29K | 242.70K | 798.45K | 980.10K | 369.60K |
| Gross Profit Ratio | 50.00% | -408.00% | 87.67% | -108.47% | -176.36% | 96.23% | 27.26% | 53.58% | 70.04% | 96.30% | 96.30% | 67.73% |
| Research & Development | 15.61M | 12.77M | 11.27M | 7.02M | 3.00M | 2.17M | 5.06M | 5.32M | 9.92M | 4.78M | 5.86M | 3.43M |
| General & Administrative | 6.71M | 6.38M | 6.65M | 6.51M | 5.57M | 6.66M | 6.41M | 6.99M | 8.96M | 6.17M | 7.67M | 4.39M |
| Selling & Marketing | 277.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.99M | 6.38M | 6.65M | 6.51M | 5.57M | 6.66M | 6.41M | 6.99M | 8.96M | 6.17M | 7.67M | 4.39M |
| Other Expenses | -216.00K | -30.00K | -79.00K | 37.00K | -5.00K | 154.77K | 734.59 | -7.91M | -2.68M | -2.14M | -2.18M | -708.18K |
| Operating Expenses | 22.38M | 19.16M | 17.92M | 13.53M | 8.56M | 8.99M | 8.68M | 4.40M | 16.20M | 8.80M | 11.35M | 7.11M |
| Cost & Expenses | 22.49M | 19.16M | 17.93M | 13.66M | 8.38M | 9.41M | 9.01M | 4.61M | 16.31M | 8.84M | 11.38M | 7.28M |
| Interest Income | 0.00 | 49.55K | 46.35K | 0.00 | 62.00K | 119.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 904.00K | 33.00K | 32.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 381.00K | 392.00K | 424.00K | 374.00K | 154.77K | 142.51K | 166.75K | 11.54M | 74.40K | 4.50M | 1.52M |
| EBITDA | -22.49M | -18.70M | -17.85M | -13.60M | -7.91M | 2.74M | -8.59M | -4.19M | -13.42M | -7.93M | -9.90M | -6.64M |
| EBITDA Ratio | -10,412.04% | -24,973.33% | -24,565.75% | -22,506.78% | -8,059.79% | 19.07% | -1,846.62% | -840.79% | -3,872.42% | -857.54% | -972.53% | -1,215.89% |
| Operating Income | -22.49M | -19.08M | -17.85M | -13.60M | -8.28M | 2.00M | -8.55M | -15.92M | -24.96M | -13.33M | -14.40M | -8.16M |
| Operating Income Ratio | -10,412.04% | -25,441.33% | -24,457.53% | -23,044.07% | -8,537.11% | 17.70% | -1,877.75% | -3,536.22% | -7,204.20% | -1,607.59% | -1,414.88% | -1,494.87% |
| Total Other Income/Expenses | 120.00K | -481.00K | -354.00K | -286.00K | 7.00K | 606.03K | 179.24K | 11.55M | 6.46M | 4.50M | 3.56M | 1.32M |
| Income Before Tax | -22.37M | -19.56M | -18.21M | -13.88M | -8.27M | 2.87M | -8.55M | -4.37M | -18.50M | -8.83M | -10.84M | -6.84M |
| Income Before Tax Ratio | -10,356.48% | -26,082.67% | -24,942.47% | -23,528.81% | -8,529.90% | 25.34% | -1,877.42% | -970.99% | -5,340.09% | -1,064.66% | -1,064.66% | -1,253.01% |
| Income Tax Expense | -619.00K | 3.00K | 354.00K | -101.00K | 27.00K | -864.22K | 1.47K | 209.79K | -9.00M | 821.46K | -4.03M | -414.32K |
| Net Income | -21.75M | -19.56M | -18.56M | -13.78M | -8.30M | 2.87M | -8.55M | -4.37M | -18.50M | -8.83M | -10.84M | -6.42M |
| Net Income Ratio | -10,069.91% | -26,082.67% | -25,427.40% | -23,357.63% | -8,557.73% | 25.34% | -1,877.42% | -970.99% | -5,340.09% | -1,064.66% | -1,064.66% | -1,177.09% |
| EPS | -5.36 | -14.12 | -38.62 | -54.54 | -138.19 | 56.89 | -207.21 | -127.11 | -663.12 | -389.77 | -611.08 | -1.45K |
| EPS Diluted | -5.36 | -14.12 | -38.62 | -54.54 | -138.19 | 56.89 | -207.21 | -127.11 | -663.12 | -389.77 | -611.08 | -1.45K |
| Weighted Avg Shares Out | 4.06M | 1.39M | 480.69K | 252.67K | 60.07K | 50.40K | 41.27K | 34.40K | 27.90K | 22.65K | 17.73K | 4.43K |
| Weighted Avg Shares Out (Dil) | 4.06M | 1.39M | 480.69K | 252.67K | 60.07K | 50.40K | 41.27K | 34.40K | 27.90K | 22.65K | 17.73K | 4.43K |
Benitec Biopharma to Present at the OPMD International Conference
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022
Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design.
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in...
Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has...
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an...
BNTC Stock Price Increased 190.28%: Why It Happened
The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by 190.28% today. This is why it happened.
Benitec BioPharma Shares Rally: Technical Levels To Watch
Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving...
What Will the Stock Market Do Today? 3 Big Stories to Watch.
What will the stock market do today? All eyes are on President Joe Biden and his spending plan, as well as Covid-19 vaccine news.
Source: https://incomestatements.info
Category: Stock Reports